Does elevated circulating TMAO increase atherosclerotic cardiovascular event risk?

Synthesis and Clinical Evidence

• Microbial Synthesis: Dietary quaternary amines (choline and L-carnitine, abundant in red meat and eggs) are metabolized exclusively by intestinal microbiota. The anaerobic glycyl radical enzyme complex CutC/D cleaves choline, while the two-component monooxygenase system CntA/B converts L-carnitine into trimethylamine (TMA).
• Hepatic Conversion: Once absorbed via the portal system, TMA is oxidized in the liver. Flavin-containing monooxygenase 3 (FMO3) is the primary driver of this process, accounting for over 90% of hepatic TMAO synthesis.
• Epidemiological Risk: Clinical cohort studies and meta-analyses consistently link elevated circulating TMAO levels to an increased risk of major adverse cardiovascular events (MACE). High plasma TMAO levels correspond to hazard ratios for MACE ranging from 1.2 to 2.5, independent of traditional cardiovascular risk factors.

Mechanistic Pathways of Vascular Injury

• Pro-inflammatory Activation: TMAO directly activates mammalian target of rapamycin (mTOR), MAPK (including p38 and ERK), and NF-κB cascades within endothelial and vascular smooth muscle cells. This signaling promotes NLRP3 inflammasome activation and increases the release of cytokines (IL-1β, IL-6, TNF-α).
• Endothelial Dysfunction: Downstream of NF-κB, TMAO upregulates vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), promoting leukocyte adhesion. Additionally, it impairs endothelial nitric oxide synthase (eNOS) phosphorylation, decreasing nitric oxide bioavailability.
• Pro-thrombotic Signaling: TMAO alters calcium homeostasis in platelets by augmenting inositol 1,4,5-trisphosphate ($IP_3$)-dependent calcium release from intracellular stores. This directly amplifies platelet hyperreactivity, adhesion to collagen, and thrombus formation. TMAO also upregulates tissue factor expression in endothelial cells and monocytes via NF-κB.

Bottom line

The claim is fully supported. Elevated circulating TMAO is a direct product of gut microbial metabolism of dietary choline and L-carnitine followed by FMO3-mediated hepatic oxidation. Once in circulation, TMAO promotes atherosclerosis and thrombotic events by activating pro-inflammatory MAPK/NF-κB pathways, disrupting endothelial function, and enhancing $IP_3$-dependent calcium release to drive platelet hyperreactivity.